Use of Probiotics in Treatment and Rehabilitation of Patients after a New Coronavirus Infection

Abstract

As of January 2022, 343 million cases of SARS-CoV-2 were reported globally. COVID-19 is a multi-faceted, multi-systemic illness in whichall age groups are susceptible. A number of research findings have shown that COVID-19 is associated with dysbiosis, leading to thedevelopment of local and systemic pathologies. It was found that the use of probiotics in the complex therapy of patients with COVID-19 reduces the severity of the disease and the development of complications. According to the researchers, several mechanisms couldexplain the therapeutic effect of probiotics, including the ability to suppress pro-inflammatory cytokine formation and modulate thefunctional activity of the immune system. In Russia, probiotics in the treatment of COVID-19 patients are only used to correct diarrhea,while literature suggests that probiotics have much greater therapeutic potential. Introducing oral bacterial therapy into the treatmentand rehabilitation of COVID-19 patients requires further clinical trials.

Keywords

• covid-19
• probiotics
• bifidobacteria
• lactobacilli
• intestinal microflora
• inflammation